<DOC>
	<DOCNO>NCT00460265</DOCNO>
	<brief_summary>The purpose study determine treatment effect Panitumumab combination chemotherapy versus chemotherapy alone first line therapy metastatic and/or recurrent squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Study Panitumumab Efficacy Patients With Recurrent and/or Metastatic Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Man woman least 18 year old . Histologically cytologically confirm metastatic and/or recurrent squamous cell carcinoma ( variant ) head neck . Diagnosis metastatic disease and/or recurrent disease follow locoregional therapy determine incurable surgery radiotherapy . Subjects receive radiation primary therapy eligible locoregional recurrence field radiation occur ≥6 month completion radiation therapy . Subjects whose locoregional recurrence solely outside field radiation eligible recurrence occur ≥ 3 month completion radiation therapy . Measurable nonmeasurable disease . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . History know presence Central Nervous System ( CNS ) metastases . History another primary cancer , except : curatively treat situ cervical cancer , curatively resect nonmelanoma skin cancer , primary solid tumor curatively treat know active disease present treatment administer ≥ 2 year randomization . Nasopharyngeal carcinoma . Prior systemic treatment metastatic and/or recurrent SCCHN Prior cisplatin contain induction chemotherapy follow cisplatin containing chemoradiotherapy Prior antiEGFr ( Epidermal growth factor receptor ) antibody therapy treatment small molecule EGFr inhibitor Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) less equal 1 year prior randomization . History interstitial lung disease ( eg , pneumonitis pulmonary fibrosis ) evidence interstitial lung disease baseline chest computerize tomography ( CT ) scan . Symptomatic peripheral neuropathy grade ≥ 2 base CTCAE v3.0 Grade ≥ 3 hearing loss base Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 Auditory/Ear ( Hearing [ without monitor program ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Epidermal Growth Factor</keyword>
	<keyword>Epidermal Growth Factor Receptor</keyword>
	<keyword>SCCHN</keyword>
	<keyword>Metastatic Head Neck Cancer</keyword>
	<keyword>EGFr</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Recurrent Head Neck Cancer</keyword>
</DOC>